Background One-third of patients with acute severe ulcerative colitis [ASUC] are steroid-
refractory. We aimed to review the different options for the management of steroid-refractory …

Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has
a variable natural course but potentially severe disease course. Since the development of …

METHODS: This single-center, double-blind, placebo-controlled trial randomized adult
patients with ASUC (defined by the Truelove Witts severity criteria) to receive either …

Background Tofacitinib has emerged as a new potential treatment for acute severe
ulcerative colitis [ASUC]. We conducted a systematic review to assess efficacy, safety and …

Objectives: Colectomy rates following acute severe ulcerative colitis have plateaued around
20% despite intravenous corticosteroid and intensified anti-tumor necrosis factor (TNF) …

Acute severe ulcerative colitis (ASUC) occurs in up to 25% of patients with ulcerative colitis
(UC). Therapeutic approaches have evolved during the past years with the increasing bio …

Introduction Tofacitinib has emerged as a useful drug for the treatment of ulcerative colitis
(UC). Areas covered There is an unmet need for cost-effective, non-immunogenic drugs with …

Acute severe ulcerative colitis (ASUC) is a distinctive ulcerative colitis flare presentation
characterised by the presence of systemic inflammation as well as bloody diarrhoea, and …

Background The advent of new therapeutic agents and the improvement of supporting care
might change the management of acute severe ulcerative colitis (ASUC) and avoid …

Abstract Background and Aims Tofacitinib (TFB) appears to be effective in the treatment of
ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB …